Does This Rapidly Growing Biotech Have Its Eye on the Future?
Can Regeneron, which generates most of its revenue from the eye disease treatment Eylea, keep climbing after a 90% rally over the past twelve months?
3 Orphan Drugmakers to Watch
Orphan drugs are driving massive gains in specialty pharmas like BioMarin Pharmaceutical, GlaxoSmithKline, and Sanofi.
Will This Biotech's Roller-Coaster Ride Ever End?
Should investors get off Clovis Oncology’s wildly volatile roller coaster before it dips again?
AstraZeneca's New Cancer Treatments Could Have Long-Term Growth Potential
Will AstraZeneca's new efforts to expand its oncology portfolio pay off in the long run?
Is Organovo Already Expanding Its Market?
A new deal with cosmetic giant L'Oreal could mean a more diversified revenue base in the future.
The 3 Biggest Biotech Dividend Stocks
Biotech dividend stocks? Nope, it's not an oxymoron. Here are 3 of the biggest: PDLI BioPharma, Questcor, and Amgen.